Tracks pregnancy and infant outcomes after relugolix-containing therapy exposure
Observes pregnant women exposed to relugolix-containing therapy and their babies.
Key facts
- Who runs it
- Sumitomo Pharma Switzerland GmbH
- Where
- Wilmington, United StatesSee the site
- Trial code
- Registry title
- Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- Status
- Recruiting
- People taking part
- 728 people, planned
- Started
- 8 May 2023
- Expected to end
- May 2033
- Type of study
- Observational, 2 groups
- Treatments tested
- Relugolix-Containing Product
- Record updated
- 19 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry follows pregnant women, some who took relugolix-containing therapy during pregnancy and some who did not, and tracks outcomes for the mother, the pregnancy and the baby.
- Age
- Women of any age.
- Sex
- Women only.
- Disease stage
- Either a woman who took at least one dose of relugolix-containing therapy during pregnancy, or a woman with a condition for which this therapy may be prescribed who did not take it during pregnancy.
- Earlier treatment
- Exposed group: at least one dose of relugolix-containing therapy during pregnancy. Unexposed group: no relugolix-containing therapy during pregnancy.
Main reasons for not taking part
- Pregnancy outcome already happened before first contact with the registry (retrospectively enrolled)
- Exposure to known teratogens or investigational medications during pregnancy
- Lost to follow-up
This trial only enrols pregnant participants. The registry sentence this rests on: Currently or recently pregnant
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Woman of any age
- Currently or recently pregnant
- Consent to participate
- Authorization for her HCP(s) to provide data to the registry; Cohort 1
- Exposure to at least one dose of relugolix-containing therapy at any time during pregnancy; Cohort 2
- Diagnosis of a condition for which relugolix-containing therapy may be prescribed and who are not exposed to relugolix containing therapy at any time during pregnancy
Who cannot take part
- Occurrence of pregnancy outcome prior to first contact with the registry coordination center (retrospectively enrolled)
- Exposure to known teratogens and/or investigational medications during pregnancy
- The following will be eligible for enrollment, included in supplementary analyses, but excluded from the analysis population:
- Lost to follow-up
Where in United States
- PPDWilmington, United StatesContact: Ronna L Chan, PH.D., M.P.H.Taking people
About the trial
What the trial wants to find out
The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.
The 2 groups in the trial
- Exposed Cohort
Pregnant women who are exposed to relugolix-containing therapy at any time during pregnancy
Treatment: Relugolix-Containing Product
- Unexposed Cohort
Pregnant women with conditions for which relugolix-containing therapy may be prescribed for indications that are approved or under phase 3 development and who are not exposed to relugolix-containing therapy at any time during pregnancy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- Plain-language title
- Tracks pregnancy and infant outcomes after relugolix-containing therapy exposureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 August 2025